{"id":44751,"date":"2023-02-01T07:24:49","date_gmt":"2023-02-01T07:24:49","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=44751"},"modified":"2023-04-10T19:25:55","modified_gmt":"2023-04-10T19:25:55","slug":"shorter-course-of-less-intensive-treatment-for-visceral-leishmaniasis","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/44751","title":{"rendered":"Shorter course of less-intensive treatment for visceral leishmaniasis"},"content":{"rendered":"
\n

Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n

\n

Results from an international study published in CID report better outcomes for treating visceral leishmaniasis with a daily combination of paromomycin and miltefosine for 14 days compared to twice-daily injections of <\/span>sodium stibogluconate and paromomycin for 17 days. [1]<\/strong><\/p>\n<\/div>\n

\n

The reduced course had fewer daily injections and was also safer.<\/span><\/p>\n<\/div>\n

\n

These findings have already been included in WHO guidelines and other information related to coinfection of HIV and visceral leishmaniasis. [2, 3]<\/span><\/p>\n<\/div>\n

\n

The study was supported by both MSF and DNDi.<\/span><\/p>\n<\/div>\n

\n

References<\/span><\/p>\n<\/div>\n

\n
    \n
  1. Musa AM et al. Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in eastern africa: a randomized, controlled, multicountry trial,\u00a0Clinical Infectious Diseases, 2022;, ciac643,\u00a0https:\/\/doi.org\/10.1093\/cid\/ciac643<\/a><\/span><\/li>\n
  2. WHO newsroom. Leishmaniasis. 12 January 2023
    \n<\/span>    https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmanias<\/a><\/li>\n
  3. WHO. WHO publishes guideline on visceral leishmaniasis and HIV coinfection. (21 June 2022)
    \n    https:\/\/www.hps.scot.nhs.uk\/publications\/hps-weekly-report\/volume-56\/issue-24\/who-publishes-guideline-on-visceral-leishmaniasis-and-hiv-coinfection\/<\/a><\/li>\n<\/ol>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base Results from an international study published in CID report better outcomes for treating visceral leishmaniasis with a daily combination of paromomycin and miltefosine for 14 days compared to twice-daily injections of sodium stibogluconate and paromomycin for …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31],"tags":[],"class_list":["post-44751","post","type-post","status-publish","format-standard","hentry","category-opportunistic-infections-coinfections-and-complications"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/44751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=44751"}],"version-history":[{"count":4,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/44751\/revisions"}],"predecessor-version":[{"id":45269,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/44751\/revisions\/45269"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=44751"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=44751"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=44751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}